Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL.
Marshall S, Nishimura N, Inoue N, Yamauchi H, Tsuyama N, Takeuchi K, Mishima Y, Yokoyama M, Ogasawara T, Mori N, Ogawa T, Sakura H, Terui Y. Marshall S, et al. Among authors: tsuyama n. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):162-169. doi: 10.1016/j.clml.2020.12.017. Epub 2020 Dec 23. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33483276 Free article.
Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.
Takahashi H, Tomita N, Sakata S, Tsuyama N, Hashimoto C, Ohshima R, Matsuura S, Ogawa K, Yamamoto W, Kameda Y, Enaka M, Inayama Y, Kasahara M, Takekawa Y, Onoda N, Motomura S, Ishigatsubo Y, Takeuchi K. Takahashi H, et al. Among authors: tsuyama n. Eur J Haematol. 2013 Apr;90(4):286-90. doi: 10.1111/ejh.12075. Epub 2013 Mar 7. Eur J Haematol. 2013. PMID: 23331211 Clinical Trial.
Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Suzuki K, Terui Y, Yokoyama M, Ueda K, Nishimura N, Mishima Y, Sakajiri S, Tsuyama N, Takeuchi K, Hatake K. Suzuki K, et al. Among authors: tsuyama n. Leuk Lymphoma. 2013 Nov;54(11):2412-7. doi: 10.3109/10428194.2013.779690. Leuk Lymphoma. 2013. PMID: 23488601
MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy.
Yamamoto E, Tomita N, Sakata S, Tsuyama N, Takeuchi K, Nakajima Y, Miyashita K, Tachibana T, Takasaki H, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Harano H, Motomura S, Ishigatsubo Y. Yamamoto E, et al. Among authors: tsuyama n. Cancer Sci. 2013 Dec;104(12):1670-4. doi: 10.1111/cas.12288. Epub 2013 Nov 27. Cancer Sci. 2013. PMID: 24112697 Free PMC article.
Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, Koyama S, Ishii Y, Yamamoto W, Takasaki H, Hagihara M, Kuwabara H, Tanaka M, Hashimoto C, Yamazaki E, Koharazawa H, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y. Tomita N, et al. Among authors: tsuyama n. Hematol Oncol. 2015 Mar;33(1):9-14. doi: 10.1002/hon.2136. Epub 2014 Feb 11. Hematol Oncol. 2015. PMID: 24519501 Clinical Trial.
146 results